Trial Profile
A phase I study of LBH589 [panobinostat] in combination with gemcitabine in the treatment of solid tumors.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Panobinostat (Primary) ; Gemcitabine
- Indications Solid tumours
- Focus Adverse reactions
- 10 Jul 2009 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
- 01 May 2009 Status changed from suspended to recruiting as reported by ClinicalTrials.gov.
- 11 Mar 2009 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.